Showing 1,881 - 1,900 results of 13,583 for search '(( significantly ((alter decrease) OR (larger decrease)) ) OR ( significant increase decrease ))', query time: 0.50s Refine Results
  1. 1881
  2. 1882
  3. 1883
  4. 1884
  5. 1885
  6. 1886
  7. 1887

    Supplementary file 2_Gut microbiome and serum metabolome alterations in osteosarcoma patients.xlsx by Chao Li (145513)

    Published 2025
    “…Principal component analysis identified 33 microbial species that exhibited significant changes in osteosarcoma patients. Of note, the relative abundance of Alloprevotella and Prevotella increased in these patients. …”
  8. 1888

    Supplementary file 1_Gut microbiome and serum metabolome alterations in osteosarcoma patients.docx by Chao Li (145513)

    Published 2025
    “…Principal component analysis identified 33 microbial species that exhibited significant changes in osteosarcoma patients. Of note, the relative abundance of Alloprevotella and Prevotella increased in these patients. …”
  9. 1889

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  10. 1890

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  11. 1891

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  12. 1892
  13. 1893
  14. 1894
  15. 1895
  16. 1896
  17. 1897
  18. 1898
  19. 1899

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  20. 1900